肝细胞癌新辅助治疗策略的研究进展  

Research progress of neoadjuvant therapy for hepatocellular carcinoma

作　　者：代尚军 李林强[1] 刘连新[1] Dai Shangjun;Li Linqiang;Liu Lianxin(Department of Liver Surgery,First Affiliated Hospital of Harbin Medical University,Harbin 150001,China)

机构地区：[1]哈尔滨医科大学附属第一医院肝脏外科,哈尔滨150001

出　　处：《中华肝胆外科杂志》2021年第12期947-950,共4页Chinese Journal of Hepatobiliary Surgery

基　　金：国家自然科学基金面上项目(81772588)。

摘　　要：原发性肝癌是全世界常见的恶性肿瘤之一,也是癌症相关死亡的主要原因,其中肝切除术是主要的治疗方案。然而,手术切除后的复发率、转移率仍然居高不下。这些问题促使更多的研究探索新辅助治疗策略,旨在改善预后和降低复发率。虽然缺乏指导治疗决策的高级别证据,但包括放射治疗和免疫治疗在内的局部和系统疗法的最新进展,提出了可能改善原发性肝细胞癌患者预后的新方法。Primary liver cancer is one of the most common malignant tumors in the world,and it is also the main cause of cancer-related death.However,the recurrence rate after surgical resection is still high.These problems have led to the development of more neoadjuvant treatment strategies aimed at improving the prognosis and reducing the recurrence rate.Despite the lack of high-level evidence to guide treatment decisions,recent advances in local and systemic therapies,including radiotherapy and immunotherapy,raise the prospect of new approaches that may improve outcomes in hepatocellular carcinoma patients.

关 键 词：癌 肝细胞 化学疗法 辅助 放射疗法 

分 类 号：R735.7[医药卫生—肿瘤]